KHRN.H — Khiron Life Sciences Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -113.54% | ||
| Return on Equity | -74.68% | ||
| Operating Margin | -202.92% | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | 0.89 | 9.58 | 8.02 | 12.79 | 19.4 | 30 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.
Directors
- Chris Naprawa CHM
- Alvaro Torres CEO (40)
- Swapan Kakumanu CFO
- Franziska Katterbach CEX
- Tejinder Virk CEX
- Deborah Rosati LED (57)
- Juan Carlos Echeverry Garzon IND (58)
- Vicente Fox Quesada IND (76)
- Alvaro Yanez IND (41)
- Last Annual
- December 31st, 2021
- Last Interim
- September 30th, 2022
- Incorporated
- May 16th, 2012
- Public Since
- October 25th, 2012
- No. of Employees
- 310
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 232,409,396
- Address
- 100 King Street West, Suite 1600, TORONTO, M5X 1G5
- Web
- https://khiron.ca/
- Phone
- +1 6475565750
- Contact
- Paola Ricardo
- Auditors
- BDO Canada LLP
Upcoming Events for KHRN.H
Similar to KHRN.H
Aequus Pharmaceuticals
TSX Venture Exchange
Avricore Health
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
As of Today at 21:37 UTC, shares in Khiron Life Sciences are trading at CA$0.04. This share price information is delayed by 15 minutes.
Shares in Khiron Life Sciences last closed at CA$0.04 and the price had moved by -72.41% over the past 365 days. In terms of relative price strength the Khiron Life Sciences share price has underperformed the Toronto Stock Exchange 300 Composite Index by -74.9% over the past year.
The overall consensus recommendation for Khiron Life Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Khiron Life Sciences does not currently pay a dividend.
Khiron Life Sciences does not currently pay a dividend.
Khiron Life Sciences does not currently pay a dividend.
To buy shares in Khiron Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.04, shares in Khiron Life Sciences had a market capitalisation of .
Here are the trading details for Khiron Life Sciences:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: KHRN
Based on an overall assessment of its quality, value and momentum Khiron Life Sciences is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Khiron Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -60.91%.
As of the last closing price of CA$0.04, shares in Khiron Life Sciences were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Khiron Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Khiron Life Sciences' management team is headed by:
- Chris Naprawa - CHM
- Alvaro Torres - CEO
- Swapan Kakumanu - CFO
- Franziska Katterbach - CEX
- Tejinder Virk - CEX
- Deborah Rosati - LED
- Juan Carlos Echeverry Garzon - IND
- Vicente Fox Quesada - IND
- Alvaro Yanez - IND